Anyone hoping for a resurgence of biotech stocks last quarter was disappointed. Even so, initial public offerings (IPOs) and follow-on offerings did make something of a recovery, up 55% and ∼25%, respectively over the fourth quarter. IPOs on European and Japanese markets had three out of the five largest IPOs of the quarter. Biotech venture capital held its ground, with most going to European companies. But total biotech funds raised from partnering and debt are down from the same quarter in 2004 by 41% and 74%, respectively.
Credit: Source: Multex, BioCentury
Credit: Source: BioCentury
Credit: Source: BioCentury
Credit: Source: BioCentury, Burrill & Company
Credit: Source: BioCentury, Hoover's, Recombinant Capital
Rights and permissions
About this article
Cite this article
Lawrence, S. Mixed results in Q1. Nat Biotechnol 23, 518 (2005). https://doi.org/10.1038/nbt0505-518
Issue Date:
DOI: https://doi.org/10.1038/nbt0505-518
